Affiliations 

  • 1 Faculty of Industrial Sciences & Technology, University Malaysia Pahang, Lebuhraya Tun Razak, Kuantan 26300, Malaysia. [email protected]
  • 2 Faculty of Industrial Sciences & Technology, University Malaysia Pahang, Lebuhraya Tun Razak, Kuantan 26300, Malaysia. [email protected]
  • 3 Faculty of Medicine and Health Sciences, University Tunku Abdul Rahman, Sungai Long 43400, Malaysia. [email protected]
  • 4 Chine-ASEAN College of Marine Sciences, Xiamen University Malaysia, Jalan Sunsuria, Bandar Sunsuria, Sepang 43900, Malaysia. [email protected]
  • 5 X-ray Crystallography Unit, School of Physics, University Sains Malaysia, Penang 11800, Malaysia. [email protected]
  • 6 X-ray Crystallography Unit, School of Physics, University Sains Malaysia, Penang 11800, Malaysia. [email protected]
  • 7 Department of Cell and Molecular Biology, Faculty of Biotechnology and Biomolecular Science, University Putra Malaysia, Serdang, Selangor Darul Ehsan 43400, Malaysia. [email protected]
  • 8 Faculty of Industrial Sciences & Technology, University Malaysia Pahang, Lebuhraya Tun Razak, Kuantan 26300, Malaysia. [email protected]
  • 9 Dr. Panjwani Center for Molecular Medicine and Drug Research, International Center for Chemical and Biological Sciences, University of Karachi, Karachi 75270, Pakistan. [email protected]
  • 10 Research Institute of Natural Products for Drug Discovery, Faculty of Pharmacy, University Teknologi MARA, Puncak Alam Campus, Bandar Puncak Alam 42300, Malaysia. [email protected]
Molecules, 2018 Mar 08;23(3).
PMID: 29518053 DOI: 10.3390/molecules23030616

Abstract

Flavokawain B (1) is a natural chalcone extracted from the roots of Piper methysticum, and has been proven to be a potential cytotoxic compound. Using the partial structure of flavokawain B (FKB), about 23 analogs have been synthesized. Among them, compounds 8, 13 and 23 were found in new FKB derivatives. All compounds were evaluated for their cytotoxic properties against two breast cancer cell lines, MCF-7 and MDA-MB-231, thus establishing the structure-activity relationship. The FKB derivatives 16 (IC50 = 6.50 ± 0.40 and 4.12 ± 0.20 μg/mL), 15 (IC50 = 5.50 ± 0.35 and 6.50 ± 1.40 μg/mL) and 13 (IC50 = 7.12 ± 0.80 and 4.04 ± 0.30 μg/mL) exhibited potential cytotoxic effects on the MCF-7 and MDA-MB-231 cell lines. However, the methoxy group substituted in position three and four in compound 2 (IC50 = 8.90 ± 0.60 and 6.80 ± 0.35 μg/mL) and 22 (IC50 = 8.80 ± 0.35 and 14.16 ± 1.10 μg/mL) exhibited good cytotoxicity. The lead compound FKB (1) showed potential cytotoxicity (IC50 = 7.70 ± 0.30 and 5.90 ± 0.30 μg/mL) against two proposed breast cancer cell lines. It is evident that the FKB skeleton is unique for anticancer agents, additionally, the presence of halogens (Cl and F) in position 2 and 3 also improved the cytotoxicity in FKB series. These findings could help to improve the future drug discovery process to treat breast cancer. A molecular dynamics study of active compounds revealed stable interactions within the active site of Janus kinase. The structures of all compounds were determined by ¹H-NMR, EI-MS, IR and UV and X-ray crystallographic spectroscopy techniques.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.